Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | ESRRA | P11474 | 1/20 | 0.37 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6564639 | 0.95 | CFTR (0.47) | CFTRGAACETPMRGPRX4AKR1C3 | |
| SCHEMBL6564379 | 0.95 | CFTR (0.47) | CFTRGAACETPMRGPRX4KDM4E | |
| SCHEMBL6566067 | 0.94 | CFTR (0.46) | CFTRGAAMRGPRX4 | |
| SCHEMBL6566526 | 0.91 | CFTR (0.43) | CFTRGAACETPMRGPRX4KDM4E | |
| SCHEMBL6565797 | 0.90 | CFTR (0.42) | CFTRGAAMRGPRX4PTGS1 | |
| SCHEMBL6566099 | 0.88 | CFTR (0.43) | CFTRGAACETPMRGPRX4KDM4E | |
| SCHEMBL6567751 | 0.88 | CFTR (0.42) | CFTRGAAMRGPRX4KDM4EALDH1A1 | |
| SCHEMBL6567957 | 0.87 | CFTR (0.48) | CFTRGAAMRGPRX4KDM4EALDH1A1 | |
| SCHEMBL6566893 | 0.87 | IDO1 (0.48) | CFTRGAAMRGPRX4KDM4EALDH1A1 | |
| SCHEMBL6566865 | 0.86 | GAA (0.46) | CFTRGAAKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | CFTR 865/4885GAA 3305/4885CETP 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.